ERBB2 mRNA expression has been previously associated with a more pronounced T-DM1 benefit in several randomized clinical trials which tested the use of T-DM1 as compared to other HER2-targeted treatments in HER2+ metastatic BC [23,24,25]. The gene discussed is ERBB2; the disease is breast cancer.